A once-daily dose of tadalafil for erectile dysfunction: Compliance and efficacy

Samuel L. Washington, Alan W. Shindel

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Abstract: Selective phosphodiesterase type 5 inhibitors (PDE5Is) have revolutionized the treatment of erectile dysfunction (ED) in men. As an on-demand treatment, PDE5Is have excellent efficacy and safety in the treatment of ED due to a broad spectrum of etiologies. Nevertheless, these drugs do have side-effect profiles that are troublesome to some patients, eg, headache, dyspepsia, myalgia, etc. Furthermore, many patients and their partners dislike the necessity of on-demand treatment for ED, citing a desire for greater spontaneity with sexual interactions. In 2008, approximately 10 years after the release of the first commercially available PDE5I, a paradigm shift in the management of ED occurred with the approval of once-daily dose of tadalafil by the US Food and Drug Administration for the management of ED. The prolonged half-life of tadalafil lends itself well to this dosing regimen and conveys the advantage of separating medication from sexual interactions; lower dose therapy also carries the theoretical benefit of lower incidence of side effects. In this study, we review the current state of the art with respect to this new management strategy for ED, highlighting published reports of the efficacy and tolerability of the daily dose tadalafil regimen.

Original languageEnglish (US)
Pages (from-to)159-171
Number of pages13
JournalDrug Design, Development and Therapy
Volume4
StatePublished - 2010

Fingerprint

Erectile Dysfunction
Compliance
Phosphodiesterase 5 Inhibitors
Therapeutics
Dyspepsia
Myalgia
United States Food and Drug Administration
Headache
Half-Life
Tadalafil
Safety
Incidence
Pharmaceutical Preparations

Keywords

  • Daily dosing
  • On-demand therapy
  • PDE5 inhibitor
  • Side effects

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Drug Discovery

Cite this

A once-daily dose of tadalafil for erectile dysfunction : Compliance and efficacy. / Washington, Samuel L.; Shindel, Alan W.

In: Drug Design, Development and Therapy, Vol. 4, 2010, p. 159-171.

Research output: Contribution to journalArticle

@article{f7d00fe7a41b4d6ab61fe6e9eddaf45f,
title = "A once-daily dose of tadalafil for erectile dysfunction: Compliance and efficacy",
abstract = "Abstract: Selective phosphodiesterase type 5 inhibitors (PDE5Is) have revolutionized the treatment of erectile dysfunction (ED) in men. As an on-demand treatment, PDE5Is have excellent efficacy and safety in the treatment of ED due to a broad spectrum of etiologies. Nevertheless, these drugs do have side-effect profiles that are troublesome to some patients, eg, headache, dyspepsia, myalgia, etc. Furthermore, many patients and their partners dislike the necessity of on-demand treatment for ED, citing a desire for greater spontaneity with sexual interactions. In 2008, approximately 10 years after the release of the first commercially available PDE5I, a paradigm shift in the management of ED occurred with the approval of once-daily dose of tadalafil by the US Food and Drug Administration for the management of ED. The prolonged half-life of tadalafil lends itself well to this dosing regimen and conveys the advantage of separating medication from sexual interactions; lower dose therapy also carries the theoretical benefit of lower incidence of side effects. In this study, we review the current state of the art with respect to this new management strategy for ED, highlighting published reports of the efficacy and tolerability of the daily dose tadalafil regimen.",
keywords = "Daily dosing, On-demand therapy, PDE5 inhibitor, Side effects",
author = "Washington, {Samuel L.} and Shindel, {Alan W.}",
year = "2010",
language = "English (US)",
volume = "4",
pages = "159--171",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - A once-daily dose of tadalafil for erectile dysfunction

T2 - Compliance and efficacy

AU - Washington, Samuel L.

AU - Shindel, Alan W.

PY - 2010

Y1 - 2010

N2 - Abstract: Selective phosphodiesterase type 5 inhibitors (PDE5Is) have revolutionized the treatment of erectile dysfunction (ED) in men. As an on-demand treatment, PDE5Is have excellent efficacy and safety in the treatment of ED due to a broad spectrum of etiologies. Nevertheless, these drugs do have side-effect profiles that are troublesome to some patients, eg, headache, dyspepsia, myalgia, etc. Furthermore, many patients and their partners dislike the necessity of on-demand treatment for ED, citing a desire for greater spontaneity with sexual interactions. In 2008, approximately 10 years after the release of the first commercially available PDE5I, a paradigm shift in the management of ED occurred with the approval of once-daily dose of tadalafil by the US Food and Drug Administration for the management of ED. The prolonged half-life of tadalafil lends itself well to this dosing regimen and conveys the advantage of separating medication from sexual interactions; lower dose therapy also carries the theoretical benefit of lower incidence of side effects. In this study, we review the current state of the art with respect to this new management strategy for ED, highlighting published reports of the efficacy and tolerability of the daily dose tadalafil regimen.

AB - Abstract: Selective phosphodiesterase type 5 inhibitors (PDE5Is) have revolutionized the treatment of erectile dysfunction (ED) in men. As an on-demand treatment, PDE5Is have excellent efficacy and safety in the treatment of ED due to a broad spectrum of etiologies. Nevertheless, these drugs do have side-effect profiles that are troublesome to some patients, eg, headache, dyspepsia, myalgia, etc. Furthermore, many patients and their partners dislike the necessity of on-demand treatment for ED, citing a desire for greater spontaneity with sexual interactions. In 2008, approximately 10 years after the release of the first commercially available PDE5I, a paradigm shift in the management of ED occurred with the approval of once-daily dose of tadalafil by the US Food and Drug Administration for the management of ED. The prolonged half-life of tadalafil lends itself well to this dosing regimen and conveys the advantage of separating medication from sexual interactions; lower dose therapy also carries the theoretical benefit of lower incidence of side effects. In this study, we review the current state of the art with respect to this new management strategy for ED, highlighting published reports of the efficacy and tolerability of the daily dose tadalafil regimen.

KW - Daily dosing

KW - On-demand therapy

KW - PDE5 inhibitor

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=79952060145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952060145&partnerID=8YFLogxK

M3 - Article

C2 - 20856843

AN - SCOPUS:79952060145

VL - 4

SP - 159

EP - 171

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -